五十年低强度治疗与低生存率:调整强化方案以治愈非洲儿童伯基特淋巴瘤
在撒哈拉以南非洲,单药环磷酰胺治疗儿童伯基特淋巴瘤(BL)已记录超过半个世纪,半数以上可治愈。高收入国家采用强化多药化疗后,最高危BL患儿治愈率超过90%,而非洲多数BL患儿仍死亡。本文综述低中收入国家及高收入国家现代强化方案前的治疗结局数据,识别改善撒哈拉以南非洲BL患儿治疗策略的潜在方向。
要点
- 非洲五十年数据显示,单药环磷酰胺治愈者多为病变局限于颌面的低分期患儿。
- 在环磷酰胺基础上加用长春新碱、低剂量甲氨蝶呤、泼尼松、多柔比星和/或低剂量阿糖胞苷未显著改善疗效。
- 高剂量甲氨蝶呤是全球儿童BL治疗的关键组成,非洲近期协作经验显示其可安全有效给药。
核心结论
- 认识到美国/欧洲与赤道非洲之间BL治愈结局存在不可接受的差距,亟需在BL流行地区资源有限条件下安全调整当代治疗方案以优化治愈结局。
研究设计与样本
- 本文为文献综述,批判性回顾低中收入国家的BL治疗结局报告,以及高收入国家在现代强化方案之前的数据。
主要发现
- 撒哈拉以南非洲单药环磷酰胺治疗儿童BL的长期治愈已记录超过半个世纪,半数以上可治愈。
- 高收入国家采用强化多药化疗后,最高危BL患儿治愈率超过90%,而非洲多数BL患儿仍死亡。
- 非洲五十年数据显示,单药环磷酰胺治愈者多为病变局限于颌面的低分期患儿。
- 在环磷酰胺基础上加用长春新碱、低剂量甲氨蝶呤、泼尼松、多柔比星和/或低剂量阿糖胞苷未显著改善疗效。
- 非洲早期引入高剂量甲氨蝶呤导致高治疗相关死亡率,但北非、西非及中美洲近期协作经验显示,尽管支持治疗资源有限,高剂量甲氨蝶呤仍可安全有效给药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Long-term cure of childhood Burkitt lymphoma (BL) in sub-Saharan Africa after treatment with single-agent cyclophosphamide has been documented for more than half of a century. Contemporary cure rates for the highest-risk patients with BL in high-income countries exceed 90% using intensive multiagent chemotherapy. By contrast, the majority of African children with BL still die. Data spanning 5 decades in Africa have repeatedly shown that the children most likely to achieve cure with limited cyclophosphamide regimens are those with lower-stage disease isolated to the jaw. Attempts to intensify the cyclophosphamide monotherapy backbone with the addition of vincristine, low-dose methotrexate, prednisone, doxorubicin, and/or low-dose cytarabine have not yielded significant improvement. High-dose methotrexate is a critical component in the treatment of childhood BL worldwide. Although initial efforts in Africa to incorporate high-dose methotrexate resulted in high treatment-related mortality, more recent collaborative experiences from North and West Africa, as well as Central America, demonstrate that it can be administered safely and effectively, despite limitations in supportive care resources. Recognizing the unacceptable disparity in curative outcomes for BL between the United States/Europe and equatorial Africa, there is a critical need to safely adapt contemporary treatment regimens to optimize curative outcomes amid the resource limitations in regions where BL is endemic. Here, we critically review reports of BL treatment outcomes from low- and middle-income countries, in addition to data from high-income countries that predated modern intensified regimens, to identify potential strategies to improve the therapeutic approach for children suffering from BL in sub-Saharan Africa.
引用
- Ozuah NW, Lubega J, Allen CE, et al. Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa. Blood Adv. 2020. PMID: 32841337. doi:10.1182/bloodadvances.2020002178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。